Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/09/20
Kura Oncology Announces Three Abstracts Accepted for Presentation at ASCO20 Virtual Scientific ProgramGlobeNewsWire • 05/13/20
Kura Oncology Announces Pricing of $125 Million Public Offering of Common StockGlobeNewsWire • 05/06/20
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/05/20
Kura Oncology Receives Fast Track Designation for Tipifarnib in T-Cell LymphomasGlobeNewsWire • 03/03/20
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/26/20
Kura Oncology Receives Fast Track Designation for Tipifarnib in HRAS Mutant HNSCC and Provides Enrollment Guidance for AIM-HN TrialGlobeNewsWire • 12/16/19
Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell LymphomaGlobeNewsWire • 12/08/19
Kura Oncology Should Be On Your Radar With Upcoming Presentation For Cancer StudySeeking Alpha • 11/21/19
Kura Oncology, Inc. (KURA) CEO Troy Wilson on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/10/19
Kura Oncology Reports Durable Anti-Tumor Activity in Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck CancerGlobeNewsWire • 10/29/19
Kura Oncology Data Selected for Oral Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/23/19
Kura Oncology Announces Upcoming Presentation at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsGlobeNewsWire • 10/16/19
Kura Oncology Doses First Patient in Phase 1 Clinical Trial of Menin-MLL Inhibitor KO-539 in Acute Myeloid LeukemiaGlobeNewsWire • 09/16/19
Kura Oncology Announces Positive Phase 2 Trial of Tipifarnib in HRAS Mutant Urothelial CarcinomaGlobeNewsWire • 09/03/19